Introduction
Bile is produced by the liver and delivered to the small intestine, where it is indispensable for the absorption of lipids and of fat soluble vitamins. Lipids are an important dietary energy source and fat soluble vitamins are vital for many processes, e.g. vitamin K deficiency leads to a disturbed balance of the blood clotting system. Hence, ongoing bile formation by the liver and undisturbed bile flow is key to vital processes in our body. A major constituent of the bile fluid are bile salts. Bile salts are amphipathic molecules and display detergent properties (Hofmann, 2009 ). As such they are toxic to cells, such as for example hepatocytes. An additional role of bile is the disposal of lipophilic metabolic end-products, xenobiotics such as dietary toxins or drugs and their metabolites. Hence, waste products secreted into bile can potentially interfere with processes involved in bile formation.
Bile salts are synthesized from cholesterol in hepatocytes, from where they are secreted into the canaliculi. From there they flow via the biliary tree into the gall bladder (except in species, which have none) (Hofmann and Hagey, 2008; Hofmann, 2009) . From the gall bladder, bile salts are released with bile into the duodenum where they promote digestion and absorption of fat. Along the small intestine, bile salts are absorbed to more than 90 % both passively and actively and transported back to the liver via the portal circulation. In the liver, bile salts are taken up into hepatocytes, from where they are secreted again into bile (Alrefai and Gill, 2007; Pellicoro and Faber, 2007; Hofmann and Hagey, 2008; Kosters and Karpen, 2008; Dawson et al., 2009 ). This circling of bile salts between the liver and the small intestine is called enterohepatic circulation.
Bile salt secretion by hepatocytes is maintained by transport systems for uptake located in the sinusoidal or basolateral membrane in coordination with export systems located in the canalicular or apical membrane of hepatocytes Trauner and Boyer, 2003; Kullak-Ublick et al., 2004; Dawson et al., 2009 ). Uptake of bile salts across the sinusoidal membrane occurs predominantly in a sodium dependent manner and is mediated by the sodium-taurocholate cotransporting polypeptide NTCP (SLC10A1) and to minor extent by the sodium independent organic anion transporting polypeptides or OATPs (members of the SLCOs) Alrefai and Gill, 2007; Dawson et al., 2009 ). In addition,
OATPs are also mediators of hepatocellular drug and xenobiotic uptake, as exemplified recently for bosentan (Treiber et al., 2007) . Knowledge on intracellular transport of bile salts from the basolateral to the apical plasma membrane is still scarce, but it is assumed that binding proteins are involved. Canalicular export occurs against a steep concentration gradient and is mediated by a member of the ATP-binding cassette (ABC) transporter family: the bile salt export pump BSEP (ABCB11) Dawson et al., 2009; Stieger, 2009 ). The rate limiting step in the overall transport from the portal blood into bile is located to the canalicular membrane of hepatocytes. Hence, proper functioning of BSEP is essential for keeping the potentially cytotoxic bile salts at a low intracellular level in hepatocytes.
Furthermore, as bile formation is an isoosmotic process, bile salts are a major driving force for the generation of canalicular bile flow. A reduction of bile flow represents a pathophysiologic situation and is called cholestais. Metabolism of bile salts within hepatocytes leads to sulphated and glucuronidated bile salts, particularly in cholestatic conditions, which are excreted into bile via the multidrug resistance protein MRP2 (ABCC2), or back into the sinusoids by MRP3 and MRP4, two salvage systems which help to reduce potentially cytotoxic intracellular bile salts (Zollner and Trauner, 2006; Geier et al., 2007) . In addition, the heterodimeric organic solute transporter OSTα-OSTβ is also expressed in the basolateral membrane (Ballatori et al., 2009 ). The relative contribution of these three adaptive efflux systems is at the moment not fully understood and needs to be worked out in detail.
The bile salt export pump Bsep has been cloned from several species including mouse, rat and human Stieger, 2009) . It is highly specific in all three species for monanionic, conjugated bile salts and all isoforms display comparably transport properties. Bsep transports barely any uncojugated bile acids (Gerloff et al., 1998) , which is supported in vivo by the observation that patients with a defect in bile acid conjugation have very little unconjugated bile acids in their bile (Carlton et al., 2003) . A comparison of rat Bsep and Mrp2 revealed no overlap in substrates (Stieger et al., 2000) . It should however be noted, that human Bsep is able to mediate transport of taurolithocholate-3-sulfate, which is not a substrate for rat Bsep (Hayashi et al., 2005) . In addition, pravastatin, but not cerivastatin, fluvastatin or pitavastatin, has been found to be transported by human and to a lesser extent by rat Bsep. Hence while the substrate specificity of Bsep is narrowed in on conjugated bile salts in all species studied, it is not identical and Bsep from different species may be able to accept additional different substrates.
As the substrates of Bsep are negative charged, they do not diffuse freely across membranes.
Therefore, assay systems have to be used, which allow access of the substrate as well as of the highly membrane-impermeable ATP to the respective binding sites located at the cytoplasmic side of Bsep. One assay system constitutes plasma membrane vesicles, which are for example isolated from the cananalicular plasma membrane (Adachi et al., 1991; Muller et al., 1991; Nishida et al., 1991; Stieger et al., 1992) or from cells transfected with Bsep. In this system, where part of the vesicles are oriented inside-out, not only ATP and the bile salt, but also other substances such as potential inhibitors have free access to the cytoplasmic portion of
Bsep. An alternate system used are sandwich cultured primary hepatocytes, which retain their bile salt transport protein polarity and secrete bile salts from the incubation medium into the canalicular lumen (Liu et al., 1999) . However, if additional substances are to be tested for interaction with Bsep, they have to cross the basolateral membrane of hepatocytes first. As a consequence, their concentration (as well as of bile salts imported via the basolateral membrane) is unknown at the time when they interact with Bsep. Importantly, these two systems have the advantage that they represent to a large extent the in vivo situation, in which multiple ABC transporters are expressed in the canalicular membrane. If Bsep is to be studied isolated from other canalicular transporters, heterologous expression systems are needed. A frequently used system is the baculovirus system in conjunction with insect cell lines, from which fractions containing Bsep expressing membrane vesicles can be isolated for transport studies (Stieger et al., 2000) . Alternate expression systems for the production of membrane vesicles are HEK293 (Hayashi et al., 2005) or Balb-3T3 cells (Green et al., 2000) . Following a different approach, polar cell lines, such as for example MCDK cells can be used for heterologous expression of hepatocellular transporters (Mita et al., 2005) . The sodiumdependent taurocholate uptake system Ntcp and the exporter Bsep localize to the basolaterateral and apical membrane domain of MDCK cells, respectively. MDCK cells can be grown in the Transwell ® system, which allows experimental access to the basolateral and to the apical cell pole of MDCK cells. Hence, hepatocellular bile salt transporters can be studied in a transcellular flux set up similar to the hepatocyte sandwich system. In principle, the different expression systems as well as the different membrane environments (for example insect versus mammalian membranes) lead to comparable results. However, recent evidence suggests that the cholesterol content of the membrane positively modulates Bsep activity (Kis et al., 2009; Paulusma et al., 2009) . In this review, data obtained from ATPase assays with Bsep will not be discussed, as so far no detailed molecular characterization of the molecular coupling of ATPase activity and of transport activity of has been published for Bsep.
Role of BSEP in liver disease
In humans, BSEP is essential in export of bile salts from hepatocytes into the canaliculus. This is evidenced by the fact the patients with inherited mutations in the ABCB11 gene resulting in the absence of functional BSEP in the canalicular membrane develop early in life severe liver disease and are at a high risk to develop liver malignancies (Strautnieks et al., 1998; Knisely et al., 2006) . Patients with mutations in the ABCB11 gene display progressive intrahepatic familial cholestasis type 2 (PFIC2) and have extremely low levels bile salts in their bile, which is indicative of a lack of canalicular bile salt secretion (Jansen et al., 1999) .
In these patients, bile salts as well as other toxic cholephilic substances accumulate within hepatocytes and ultimately lead to hepatocyte necrosis. The lack of bile salts in the bile of these patients leads to alterations in intestinal lipid and fat soluble vitamin absorption, the latter putting them at risk for impairment of blood clotting. Not all mutations in the ABCB11 gene lead to a severe clinical phenotype, but also to milder forms such as benign recurrent Functional characterization of the E297G variant of BSEP revealed residual transport activity (Noe et al., 2005) . The fact that mutations in the ABCB11 also lead to a benign recurrent form of cholestatsis raises the question on the minimal amount of functional BSEP secreting bile salts, which is needed in the canaliculus for normal liver function. This question will be difficult to answer, as access to human liver tissue, in particular from healthy livers, is very limited and information on bile salt secretion from patients is usually not available. A comparison of BSEP expression levels (among other canalicular ABC-transporters) in 110 healthy liver tissue samples demonstrated a considerable variation of BSEP expression levels in normal human liver tissue .
Role of BSEP in acquired cholestasis
The observation that some mutations of BSEP having residual transport activity lead to mild forms of BSEP deficiency syndrome provides a pathophysiological basis for the concept that inhibition of BSEP by drugs or xenobiotics can lead to acquired intrahepatic cholestasis. For example, in a patient with benign recurrent intrahepatic cholestasis type 2, the two compound heterozygous mutations E297G and R432T were identified. BSEP staining in a liver biopsy revealed normal canalicular staining. However, individual in vitro kinetic characterization of the two mutant BSEP forms demonstrated a massively reduced v max value of the two forms with no relevant change in the Km value for taurocholate (Noe et al., 2005) . Hence, the overall capacity for canalicular secretion of bile salts is massively reduced in this patient. It can be speculated that in symptom-free intervals, this residual transport capacity is sufficient to allow a seemingly normal liver function, which in the cholestatic episodes is probably further impaired by other yet unknown factors. In addition, Bsep can be inhibited by endogenous metabolites, such as for example aberrant bile salts, which occur in patients with inborn errors in the biosynthesis of bile salts inhibit Bsep (Stieger et al., 1997) . If untreated, this disease also manifests with progressive cholestasis (Sundaram et al., 2008) .
While inherited severe BSEP deficiency syndromes are very rare, drug induced liver injury including cholestasis is a relevant clinical issue leading to many hospital admissions ending in severe cases with liver transplantation (Bleibel et al., 2007) . In addition, drug induced liver injury is an important factor leading attrition of drugs during development or to withdrawal of drugs from the market (Schuster et al., 2005; Smith and Schmid, 2006) . Hence, drug induced liver injury poses a significant burden to the costs of modern health care systems.
Unfortunately, the underlying pathogenetic mechanism(s) of drug induced liver injury often remain(s) enigmatic (hence the term idiosyncratic liver injury). After the cloning of rat Bsep as the first bile salt export pump, it could be demonstrated that some drugs are able to inhibit Bsep and hence can cause drug-induced cholestasis (Stieger et al., 2000 (Treiber et al., 2007) . During clinical trials, bosentan was observed to cause asymptomatic, reversible transaminase elevations in some patients (Fattinger et al., 2001 ). The incidence of liver injury was dose dependent as plasma bile salt levels in affected individuals increased with increasing dose of bosentan. Furthermore, individuals, which in addition to bosentan were taking glyburide, showed a higher incidence of liver injury than patients who were on bosentan alone. Studies with rat Bsep expressed in Sf9 cell vesicles subsequently demonstrated that bosentan and one of its metabolites are competitive Bsep inhibitors (table 1) . Also, bosentan treatment of rats lead, as in humans; to an elevation of plasma bile salt levels, which was more pronounced if glibenclamide was coadministered (Fattinger et al., 2001) . After cloning of human BSEP, bosentan turned out to be a competitive inhibitor of BSEP, too (table 1) . Therefore, the fact that the serum bile salt levels positively correlated with the bosentan dose as well as the spontaneous normalization of serum liver parameters after stopping of bosentan strongly suggest that also in vivo in human liver bosentan acts as a competitive BSEP inhibitor. This effect could be rather specific on BSEP, as no elevation of serum bilirubin was observed (Fattinger et al., 2001 ). The list of Bsep/BSEP inhibitors is continuosly growing and examples are given in table 1.
Troglitazone is an example of a drug, which was withdrawn from the market due to its hepatotoxicity. The exact mechanisms of its toxic action remain somewhat enigmatic, but a consensus has emerged that that troglitazone are toxic to mitochondria (Masubuchi, 2006; Julie et al., 2008) . In addition, troglitazone administration in rats leads to an acute reduction to bile flow and hence is cholestatic (Preininger et al., 1999) . Troglitazone-sulphate is the main metabolite of troglitazone in rats and excreted into bile ). Both, the parent compound and its sulphated metabolite are competitive inhibitors of rat canalicular plasma membrane vesicles (table 1) . Recently, troglitazone was also found to be an inhibitor of dog and human BSEP (table 1) . Hence, troglitazone can negatively impact mitochondria directly as well as by inhibiting BSEP followed by an accumulation of bile salts in hepatocytes. Bile salts by themselves are toxic to mitochondria (Krahenbuhl et al., 1994) . Drug induced liver injury often results not only in cholestatic but in mixed (hepatocellular and cholestatic) liver injury . Using as additional thiazolidinediones, both rosiglitazone and ciglitazone inhibit taurocholate transport into rat canalicular plasma membrane vesicles, suggesting a class effect on Bsep inhibition (Snow and Moseley, 2007) . This clearly demonstrates that the toxicity of troglitazone requires additional mechanisms to its cholestatic potential.
Cholestasis of pregnancy is a rare complication of pregnancies and shows marked regional differences in incidence (Zollner and Trauner, 2006) . This is an indication that genetic factors are important in rendering patients susceptible to this form of cholestasis. Furthermore, metabolites of estrogen and/or progesterone are implicated in its pathogenesis. Hence, intrahepatic cholestasis of pregnancy is also an acquired form of cholestasis. Estrogen metabolites are also involved in cholestasis induced by oral contraceptives. In animal experiments, estradiol-17β-glucuronide has been demonstrated to be strongly cholestatic (Huang et al., 2000) . Its cholestatic action is dependent on the expression of Mrp2 in the canaliculus. Interestingly and surprisingly, estradiol-17β-glucuronide did not inhibit taurocholate transport in Sf9 cell vesicles expressing Bsep (Stieger et al., 2000) . However, if in the same vesicles Bsep and Mrp2 were coexpressed, estradiol-17β-glucuronide inhibits
Bsep mediated taurocholate transport activity in a time-and dose-dependent manner. This is in line with the observation in rats that Mrp2 is strictly required for the cholestatic potential of estradiol-17β-glucuronide. Hence, Bsep can also be indirectly inhibited and it was postulated that estradiol-17β-glucuronide inhibits Bsep by trans-inhibition, i.e. it needs to be secreted into the canalicular lumen to exert its inhibitory and consequently cholestatic property. This result was later confirmed and extended to sulphated progesteron metabolites (Akita et al., 2001; Vallejo et al., 2005) . The same inhibitory principle is also described for the epidermal growth factor receptor inhibitor PKI166 (Takada et al., 2004) .
Most interestingly, in an extension of the investigation of the cholestatic potential of bosentan in rats it was found that bosentan leads to a stimulation of bile flow and not -as expected -to a reduction of bile flow (Fouassier et al., 2002) . While bile flow was increased, bile salt output remained unchanged with a consequently lower bile salt concentration in bile. The stimulation of the bile flow was again dependent on the presence of functional Mrp2 in the canaliculus. Hence, bosentan presents an additional example of the involvement of Mrp2 in the cholestatic effect of a substance. A study using rat and human Mrp2/MRP2 as well as
Bsep/BSEP expressed in Sf9 cells confirmed the inhibition by bosentan of both isoforms of Bsep/BSEP (Mano et al., 2007) . Moreover it demonstrated that the transport activity of Mrp2/MRP2 was stimulated by bosentan, which explains the observed increase of bile salt independent bile flow in rats. Taken together, Bsep can either be inhibited directly by drug form the cytoplasm or indirectly, most probably from the canalicular side. This process seems to need the presence of Mrp2.
Susceptibility to Acquired Cholestasis
Drug induced cholestasis a relevant and often severe clinical issue. However, the risk for such an event is rare (Russmann et al., 2005) . One such risk factor could for example be the Saito et al., 2002; Pauli-Magnus et al., 2004; Lang et al., 2006) .
Investigation of the expression of four canalicular ABC transporters including BSEP in 110 healthy liver samples revealed that the p.V444A variant tended to lower BSEP expression levels . Kinetic characterization of the two BSEP isoforms in the Sf9 cell expression system demonstrated indiscernible transport properties of the V444 and the A444 BSEP variant (Lang et al., 2007) . Hence, individuals carrying the p.V444A variant could be more prone to acquired cholestais. This hypothesis is supported by the observation that in patients with drug induced cholestasis as well as in patients with cholestasis of pregnancy the frequency of c.1331T>C is significantly higher than in controls (Lang et al., 2007; Meier et al., 2008; Dixon et al., 2009) . These three studies therefore suggest that the c.1331T>C
(p.V444A) variant of ABCB11 could be a susceptibility factor for acquired cholestasis. In addition and in further support of these results, three case reports describing two patients with cholestasis of pregnancy and one patient with benign recurrent intrahepatic cholestasis type 2 identified homocygosity for 1331T in one and heterozygosity for this variant in two patients Kubitz et al., 2006; Muehlenberg et al., 2008 ). An extensive in vitro characterization of the impact of mutations and single-nucleotide polymorphisms in the ABCB11 gene found that the 1331T variant leads to lower expression levels of BSEP in CHO cells (Byrne et al., 2009) . Hence this finding represents additional support for the hypothesis that the 1331T variant of the ABCB11 gene could be a susceptibility factor for acquired cholestasis and confirms the findings from the study on BSEP protein expression in healthy human liver tissue. Clearly, larger prospective studies in independent cohorts are now needed to confirm this finding, in particular as a study in a Swedish cohort of women with intrahepatic cholestasis of pregnancy found no difference in the distribution of common BSEP haplotypes (Wasmuth et al., 2007) . It is important to note that the latter study compared haplotypes, while the other studies investigated frequencies of single nucleotide polymorphisms.
Conclusion
In conclusion, impairment of the function of BSEP either by inherited mutations or by single nucleotide polymorphisms as well as by inhibition of its transport activity can lead to cholestasis, which in some patients develops into severe liver disease. Kinetic characterization of rodent and human BSEP as well as studies on the inhibition of rodent and human Bsep have shown that these isoforms have comparable kinetic properties. However, for several reasons, this approach should be used cautiously: First, the substrate specificity of rat and human Bsep is similar, but not identical (Stieger et al., 2000; Hayashi et al., 2005) . Second, kinetic parameters both for substrates and inhibitors are comparable, but not identical (table 1) .
Hence, extrapolation from preclinical rodent data to the human in vivo situation may be difficult. However, if an inhibition of Bsep in rodent systems is observed either in vitro or in vivo, this clearly rises a flag for human studies and warrants in such studies to closely follow serum bile salt levels. Third mice with an ablated Abcb11 gene do not present with severe cholestasis on a normal diet (Wang et al., 2001) . Only if these mice are put on high cholate diet, they will develop severe cholestasis, which leads to rapid death of male, but not female mice (Wang et al., 2003) . Mice with absent Bsep secrete novel tetrahydroxylated bile salts into their bile (Wang et al., 2001) , which highlights the important interplay of bile salt metabolism and transport to protect hepatocytes from bile salt toxicity. Furthermore, these mice present with highly upregulated p-glycoprotein, which in vitro can transport bile salts and hence could potentially act as a salvage system (Lam et al., 2005) .
While it is well established now that inhibition of BSEP by drugs and other xenobiotics can lead to cholestasis, a better understanding of the factors rendering individuals susceptible to such outcomes is clearly needed. This will require both, prospective clinical studies in conjunction with genome wide analysis, such as it was recently reported for statin-induced myopathy (Link et al., 2008) as well as further investigation on molecular aspects of Bsep, keeping both, direct and indirect inhibition of BSEP in mind. And finally, with the growing list of known Bsep inhibitors, it seems feasible that quantitative structure-activity relationship analysis will lead to a better understanding of the chemical properties of Bsep inhibitors (Hirano et al., 2006) .
